SCHEMBL4767199

SCHEMBL4767199

COc1o[c]nc1-c1cccc2ccccc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 1/20 0.38
PGK1 P00558 1/20 0.37
ALOX15 P16050 2/20 0.37
ALDH1A1 P00352 5/20 0.36
MAPT P10636 5/20 0.35
SMN1; SMN2 Q16637 4/20 0.35
RAB9A P51151 2/20 0.35
ENPP3 O14638 1/20 0.35
ENPP1 P22413 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
PDGFRB P09619 1/20 0.35
HPGD P15428 2/20 0.35
KDM4E B2RXH2 1/20 0.35
TP53 P04637 1/20 0.35
TSHR P16473 1/20 0.35
NFKB1 P19838 1/20 0.35
MAPK1 P28482 1/20 0.35
NFKB2 Q00653 1/20 0.35
RELA Q04206 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4720960 0.84 ENPP1 (0.42) BCHEPGK1ALOX15ALDH1A1MAPT
SCHEMBL4720155 0.81 TDP1 (0.39) BCHEALOX15ALDH1A1TDP1L3MBTL1
SCHEMBL4724452 0.74 LMNA (0.40) ALDH1A1MAPTSMN1; SMN2RAB9AENPP3
SCHEMBL4720658 0.70 PGK1 (0.37) BCHEPGK1ALOX15ALDH1A1MAPT
SCHEMBL4724379 0.70 ALOX15 (0.40) ALOX15ALDH1A1MAPTSMN1; SMN2RAB9A
SCHEMBL4765413 0.69 PGK1 (0.41) BCHEPGK1ALDH1A1MAPTSMN1; SMN2
Methoxymethane SCHEMBL15104847 0.68 ALDH1A1 (0.50) ALOX15ALDH1A1MAPTSMN1; SMN2RAB9A
SCHEMBL17831846 0.68 ALOX15 (0.48) ALOX15ALDH1A1MAPTSMN1; SMN2RAB9A
SCHEMBL6051921 0.67 ALDH1A1 (0.41) BCHEALOX15ALDH1A1MAPTSMN1; SMN2
SCHEMBL6311868 0.65 ALDH1A1 (0.39) PGK1ALOX15ALDH1A1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 BCHE 3103/4885PGK1 1835/4885ALOX15 1066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.